Skip to main content
Premium Trial:

Request an Annual Quote

Agilent's Dako Lands FDA Approval for Lung Cancer Complementary Dx

NEW YORK (GenomeWeb) – Agilent Technologies today announced its subsidiary Dako has received US Food and Drug Administration approval for a complementary diagnostic for Bristol-Myers Squibb's non-squamous non-small cell lung cancer (NSCLC) drug Opdivo (nivolumab).

The complementary diagnostic, PD-L1 IHC 28-8 pharmDx, identifies PD-L1 expression levels on the surface of NSCLC cells and provides information on the survival benefit of treatment with Opdivo.

At a recent conference in Washington, DC, the agency discussed its thinking around complementary diagnostics. This kind of complementary test, according to the agency, may be used to define a subset of patients that respond particularly well to a drug and aid in risk/benefit assessments, but unlike a companion diagnostic, the test isn't a prerequisite for receiving the drug.

PD-L1 testing is not required for the use of Opdivo, but it may provide additional information for physicians and inform patient dialogue, the FDA said in a statement.

The firm also said that the FDA today expanded the indication for Opdivo to include previously treated non-squamous NSCLC in addition to the squamous NSCLC indication.

Dako began working on the complementary diagnostic in partnership with Japanese firm Ono Pharmaceutical in February. Bristol-Meyers Squibb holds global development and commercialization rights to Opdivo outside of Japan, South Korea, and Taiwan.

Last week, Dako announced that the FDA had approved its PD-L1 IHC 22C3 pharmDx test as a  companion diagnostic alongside Merck's anti-PD-1 therapy Keytruda (pembrolizumab).

This article has been updated from an earlier version to correctly state that the FDA approved a complementary diagnostic, not a companion diagnostic, for Opdivo.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.